Imfinzi Approved in the US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

August 16, 2024

Imfinzi approved in the US for treating resectable non-small cell lung cancer before and after surgery, based on the AEGEAN trial showing a 32% reduction in risk of recurrence.

Highlighted Terms

Food and Drug Administration Lung Ambition Alliance non-small cell lung cancer AstraZeneca The University of Texas MD Anderson Cancer Center FDA NSCLC Imfinzi durvalumab Oncology Business Unit

Related News

drugs.com

Imfinzi Approved in the US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Imfinzi approved in the US for treating resectable non-small cell lung cancer before and after surgery, based on the AEGEAN trial showing a 32% reduction in risk of recurrence.